Long-term efficacy of endovascular ultrasound renal denervation in resistant hypertension: 6-year results from the ACHIEVE study

Long-term efficacy of endovascular ultrasound renal denervation in resistant hypertension: 6-year results from the ACHIEVE study - ACHIEVE Long-term Follow-up Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00029639

Enrollment

Registered

2022-07-25

Start date

2021-09-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I10 I11 I12 N18

Interventions

Group 1: Patients who underwent renal sympathetic denervation in the context of the prospective, multicenter, nonrandomized, postmarket ACHIEVE study performed at eight centers in three European count

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Initial enrolment in the ACHIEVE-study; - Treated with the Paradise renal denervation system; - Informed consent; - The patient agrees to follow-up.

Exclusion criteria

Exclusion criteria: Not Applicable

Design outcomes

Primary

Measure	Time frame
Change in 24h ambulatory systolic BP between baseline and 6 years after renal sympathetic denervation.	—

Secondary

Measure	Time frame
Change in 24h ambulatory systolic BP between baseline and 6 years after RDN; 6-year survival status, occurrence of Major Adverse Events (MAE), change in office systolic and diastolic BP between baseline and 6 years, change in 24h ambulatory diastolic BP between baseline and 6 years after RDN, change in daytime systolic and diastolic ambulatory BP between baseline and 6 years after RDN, change in nighttime systolic and diastolic ambulatory BP between baseline and 6 years after RDN, change in number of defined daily doses of antihypertensive drugs between baseline and 6 years after RDN, change in estimated Glomerular Filtration Rate (eGFR) between baseline and 6 years after RDN, change in office BP measurements performed between 1 and 6 years, change in ambulatory BP measurements performed between 1 and 6 years, change in number of DDDs of antihypertensive drugs between 1 and 6 years and change in eGFR between 1 and 6 years after RDN.	—

Measure

Time frame

Change in 24h ambulatory systolic BP between baseline and 6 years after RDN; 6-year survival status, occurrence of Major Adverse Events (MAE), change in office systolic and diastolic BP between baseline and 6 years, change in 24h ambulatory diastolic BP between baseline and 6 years after RDN, change in daytime systolic and diastolic ambulatory BP between baseline and 6 years after RDN, change in nighttime systolic and diastolic ambulatory BP between baseline and 6 years after RDN, change in number of defined daily doses of antihypertensive drugs between baseline and 6 years after RDN, change in estimated Glomerular Filtration Rate (eGFR) between baseline and 6 years after RDN, change in office BP measurements performed between 1 and 6 years, change in ambulatory BP measurements performed between 1 and 6 years, change in number of DDDs of antihypertensive drugs between 1 and 6 years and change in eGFR between 1 and 6 years after RDN.

—

Countries

Germany, Netherlands, Sweden

Contacts

Public ContactJoost Daemen

Erasmus University Medical Center

j.daemen@erasmusmc.nl+31 10 704 0 704

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026